Showing results (1141-1150 of 5,693) with videos related to

Sort By:
Pageof 570
The Oncologist|February 13, 2023
BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal CancerJulia C F Quintanilha, Ryon P Graf, Geoffrey R Oxnard
The Oncologist|February 28, 2023
Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete RemissionKaviyon Sadrolashrafi, Wolfram Samlowski
The Oncologist|February 17, 2026
Partial breast irradiation versus whole breast irradiation after breast-conserving surgery in early-stage breast cancer: a systematic reviewSara Garduño-Sánchez, María Isabel Villanego-Beltrán, Francisco Javier Carrasco-Sánchez, et al.
The Oncologist|February 17, 2026
MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterationsElizabeth D Auckley, Stephanie Yohay, Grace Ying, et al.
The Oncologist|March 4, 2025
Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patientsEyal Yosefof, Nofar Edri, Idan Ben-Nachum, et al.
The Oncologist|March 4, 2025
Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapyFangyuan Zhang, Zixuan Ding, Yongping Lian, et al.
The Oncologist|February 25, 2025
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) studyMaribel Del Olmo-García, Lorena Hernandez-Rienda, Rocio Garcia-Carbonero, et al.
The Oncologist|January 23, 2025
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreductionVincent Chung, Angela Alistar, Carlos Becerra, et al.
The Oncologist|January 21, 2025
Liver transplantation for colorectal cancer with liver metastasesBenjamin E Ueberroth, Michael Kriss, James R Burton, et al.
The Oncologist|November 16, 2024
Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysisKe Wang, Ting Xu, Jing Wu, et al.
Pageof 570